The EMBO Journal · 2013 · 337 citations · 41 references
Life SciencesImmunologyMolecular BiologyGene ExpressionInnate ImmunityMolecular VirologyDna DamageDna Damage SignalingInnate Immune ResponseInnate Immune Signaling PathwaysInterferon ResponsesReplication Stress ResponseAntiviral Interferon ResponsesDna Damage Response GenesDna Damage Response PathwaysDna Damage Response SignalingResistance To Viral Infection
A single high dose of interferon-β (IFNβ) activates powerful cellular responses, in which many anti-viral, pro-apoptotic, and anti-proliferative proteins are highly expressed. Since some of these proteins are deleterious, cells downregulate this initial response rapidly. However, the expression of many anti-viral proteins that do no harm is sustained, prolonging a substantial part of the initial anti-viral response for days and also providing resistance to DNA damage. While the transcription factor ISGF3 (IRF9 and tyrosine-phosphorylated STATs 1 and 2) drives the first rapid response phase, the related factor un-phosphorylated ISGF3 (U-ISGF3), formed by IFNβ-induced high levels of IRF9 and STATs 1 and 2 without tyrosine phosphorylation, drives the second prolonged response. The U-ISGF3-induced anti-viral genes that show prolonged expression are driven by distinct IFN stimulated response elements (ISREs). Continuous exposure of cells to a low level of IFNβ, often seen in cancers, leads to steady-state increased expression of only the U-ISGF3-dependent proteins, with no sustained increase in other IFNβ-induced proteins, and to constitutive resistance to DNA damage.
41
WebLogo: A Sequence Logo Generator: Figure 1
Gavin E. Crooks, Gary C. Hon, John‐Marc Chandonia et al. · Genome Research · 2004 · 13K citations · Full text
A diverse range of gene products are effectors of the type I interferon antiviral response
John W. Schoggins, Sam J. Wilson, Maryline Panis et al. · Nature · 2011 · 2.5K citations